Literature DB >> 8868478

Synthesis, structure, and structure-activity relationships of divalent thrombin inhibitors containing an alpha-keto-amide transition-state mimetic.

R Krishnan1, A Tulinsky, G P Vlasuk, D Pearson, P Vallar, P Bergum, T K Brunck, W C Ripka.   

Abstract

A new class of divalent thrombin inhibitors is described that contains an alpha-keto-amide transition-state mimetic linking an active site binding group and a group that binds to the fibrinogen-binding exosite. The X-ray crystallographic structure of the most potent member of this new class, CVS995, shows many features in common with other divalent thrombin inhibitors and clearly defines the transition-state-like binding of the alpha-keto-amide group. The structure of the active site part of the inhibitor shows a network of water molecules connecting both the side-chain and backbone atoms of thrombin and the inhibitor. Direct peptide analogues of the new transition-state-containing divalent thrombin inhibitors were compared using in vitro assays of thrombin inhibition. There was no direct correlation between the binding constants of the peptides and their alpha-keto-amide counterparts. The most potent alpha-keto-amide inhibitor, CVS995, with a Ki = 1 pM, did not correspond to the most potent divalent peptide and contained a single amino acid deletion in the exosite binding region with respect to the equivalent region of the natural thrombin inhibitor hirudin. The interaction energies of the active site, transition state, and exosite binding regions of these new divalent thrombin inhibitors are not additive.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8868478      PMCID: PMC2143369          DOI: 10.1002/pro.5560050303

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  39 in total

1.  Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin.

Authors:  J M Maraganore; P Bourdon; J Jablonski; K L Ramachandran; J W Fenton
Journal:  Biochemistry       Date:  1990-07-31       Impact factor: 3.162

2.  Hirulog peptides with scissile bond replacements resistant to thrombin cleavage.

Authors:  T Kline; C Hammond; P Bourdon; J M Maraganore
Journal:  Biochem Biophys Res Commun       Date:  1991-06-28       Impact factor: 3.575

3.  Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation.

Authors:  T K Vu; D T Hung; V I Wheaton; S R Coughlin
Journal:  Cell       Date:  1991-03-22       Impact factor: 41.582

4.  Stereochemically restrained refinement of macromolecular structures.

Authors:  W A Hendrickson
Journal:  Methods Enzymol       Date:  1985       Impact factor: 1.600

Review 5.  Thrombin.

Authors:  J W Fenton
Journal:  Ann N Y Acad Sci       Date:  1986       Impact factor: 5.691

6.  Amino acid sequence of the heavy chain of bovine protein C.

Authors:  J Stenflo; P Fernlund
Journal:  J Biol Chem       Date:  1982-10-25       Impact factor: 5.157

7.  The kinetics of reversible tight-binding inhibition.

Authors:  J W Williams; J F Morrison
Journal:  Methods Enzymol       Date:  1979       Impact factor: 1.600

8.  Bifunctional thrombin inhibitors based on the sequence of hirudin45-65.

Authors:  J DiMaio; B Gibbs; D Munn; J Lefebvre; F Ni; Y Konishi
Journal:  J Biol Chem       Date:  1990-12-15       Impact factor: 5.157

9.  A new class of potent thrombin inhibitors that incorporates a scissile pseudopeptide bond.

Authors:  J DiMaio; F Ni; B Gibbs; Y Konishi
Journal:  FEBS Lett       Date:  1991-04-22       Impact factor: 4.124

10.  Structure of a tetrahedral transition state complex of alpha-chymotrypsin dimer at 1.8-A resolution.

Authors:  A Tulinsky; R A Blevins
Journal:  J Biol Chem       Date:  1987-06-05       Impact factor: 5.157

View more
  4 in total

1.  Hirunorms are true hirudin mimetics. The crystal structure of human alpha-thrombin-hirunorm V complex.

Authors:  G De Simone; A Lombardi; S Galdiero; F Nastri; R Della Morte; N Staiano; C Pedone; M Bolognesi; V Pavone
Journal:  Protein Sci       Date:  1998-02       Impact factor: 6.725

2.  Crystal structures of thrombin with thiazole-containing inhibitors: probes of the S1' binding site.

Authors:  J H Matthews; R Krishnan; M J Costanzo; B E Maryanoff; A Tulinsky
Journal:  Biophys J       Date:  1996-11       Impact factor: 4.033

3.  Rational design and characterization of D-Phe-Pro-D-Arg-derived direct thrombin inhibitors.

Authors:  Ana C Figueiredo; Cristina C Clement; Sheuli Zakia; Julian Gingold; Manfred Philipp; Pedro J B Pereira
Journal:  PLoS One       Date:  2012-03-23       Impact factor: 3.240

4.  Anticoagulants Influence the Performance of In Vitro Assays Intended for Characterization of Nanotechnology-Based Formulations.

Authors:  Edward Cedrone; Barry W Neun; Jamie Rodriguez; Alison Vermilya; Jeffrey D Clogston; Scott E McNeil; Yechezkel Barenholz; Janos Szebeni; Marina A Dobrovolskaia
Journal:  Molecules       Date:  2017-12-21       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.